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Keloid scars may be painful, itch severely and be cos-
metically disturbing. The burden of keloid disease, 
how ever, has not yet been determined. This study eva-
luated the association of keloid disease with health-
related quality of life (HRQL) and identified indicators 
of burden using a cross-sectional survey study, with 
one disease-specific HRQL measure (Skindex-29) and 
2 generic HRQL measures (SF-36 and EQ-5D-5L). A to-
tal of 106 keloid patients with no other skin diseases 
participated in the study. Having keloid disease was 
associated with a considerable impairment of emotio-
nal wellbeing, with most impairment on the emotional 
and mental HRQL. Pain and itch were the strongest in-
dicators of HRQL impairment in keloid patients. Having 
painful or itchy keloids was related to low mental and 
emotional HRQL, implying that patients with keloids 
require access to effective treatment aimed at allevia-
ting physical symptoms.
Key words: keloid; health-related quality of life; POSAS; Skin-
dex-29; SF-36; EQ-5D.
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Keloids are abnormal scars, which act like benign tumours growing beyond the margins of the original 
wound (1). Additional physical symptoms, such as itch 
and pain, occur in up to 80% of patients (1, 2). Keloid 
disease can lead to aesthetic, physical and psychological 
complaints in affected individuals (3, 4). Treatment has 
varying results and is associated with a high degree of 
resistance to treatment and recurrence (5). 
The advent of health-related quality of life (HRQL) 
measures has greatly improved our insight into the 
burden of skin diseases. Skin diseases (e.g. psoriasis) 
may negatively affect HRQL to a degree comparable 
to or exceeding that of life-threatening illnesses, such 
as myocardial infarction and heart failure (6). Thus, the 
impact of skin diseases should not be underestimated, 
and HRQL research is warranted for all skin conditions.
The limited research available on HRQL of patients 
with scars shows negative effects on physical, psycho-
logical and social well-being (3, 4, 7–9). These studies, 
however, have substantial limitations, most importantly, 
a failure to differentiate between hypertrophic scars 
(HTS) and keloids, while these conditions are distinct-
ly different from one another. HTS stay within the 
original wound margins, are self-limiting, and respond 
considerably better to treatment with lower recurrence 
rates (10). Preservation of HRQL is more likely with 
favourable symptoms, prognosis and duration of HTS 
compared with keloids. Research on these 2 conditions 
combined probably underestimates the burden of the 
more severe condition, keloid disease. In addition, none 
of these studies evaluated the effect of keloids on HRQL 
using both disease-specific and generic health measures. 
Generic health measures allow comparison of the burden 
of keloids with that of other major diseases. Thus, the de-
gree of burden of keloids can be illustrated and the need 
for effective treatment can be formally prioritized. The 
combined use of different HRQL instruments provides 
such a broad and sensitive assessment of the burden of 
skin diseases (11).
METHODS
The present study was a multi-centre cross-sectional online survey.
Participants
All adults diagnosed with keloid disease by an experienced 
physician from the participating Departments of Plastic and Re-
constructive Surgery and Dermatology at 2 university hospitals 
were eligible. Diagnosis of keloid disease was made on clinical 
presentation, most important continuous growth, beyond wound 
borders, without spontaneous regression after one year. Patients 
were excluded if there was any doubt about the diagnosis, or if 
the diagnosis differed between physicians. Patients, who were 
not proficient in Dutch, no longer had a keloid, or had additional 
skin diseases, were excluded. All respondents completed an online 
informed consent form and a series of self-administered ques-
tionnaires between February and May 2014. Non-responders were 
contacted by telephone after 3 weeks to invite them to participate.
Questionnaires
Patient and Observer Scar Assessment Scale (POSAS). Scar 
severity was subjectively assessed using the patient scale of this 
validated scar assessment tool (PSAS), consisting of 6 items on 
pain, itch, colour, stiffness, thickness, and irregularity, as well as 
an overall opinion on the scar. All items as well as overall opinion 
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were rated on a 10-point scale (13). Higher scores represent a more 
severe scar. A threshold of >3 on the pain and itch items was used 
to indicate substantial symptoms (14, 15).
SF-36. This widely used generic HRQL questionnaire contains 36 
questions that provide scores on 8 different dimensions of functio-
nal health and well-being. Scores are given on a 100-point scale, 
with higher scores indicating better quality of life. Norm-based 
physical component summary scores (PCS) and mental component 
summary scores (MCS) (mean 50, SD 10) were calculated using 
pooled-age-matched norm scores from a Dutch urban (Amsterdam) 
reference population (16).
Besides the above-mentioned questionnaires, the Skindex-29 
(17, 18) and EQ-5D-5L (19) were also used. These results have 
been reported previously (12). 
Independent measures
Socio-demographic and clinical characteristics, including sex, age, 
skin colour as described by Fitzpatrick, location and visibility of 
the keloid, number of keloids (quantity), disease duration, origin of 
the keloid, previous treatments, and comorbidities, were collected.
Statistical analysis
Characteristics of the study population were analysed using des-
criptive statistics. Cohen’s d effect sizes were calculated; values 
> 0.20 were considered small effects, > 0.50 medium effects, and 
> 0.80 large effects (20).
Correlations were calculated between the independent variables 
and the 4 Skindex-29 scales, the SF-36 PCS and MCS scales, and 
EQ-5D-5L index scale. Previously-reported data from Skindex-29 
and EQ-5D-5L instruments were also used to improve the validity 
of the correlation and regression analysis. 
Pearson’s correlation coefficients (rp) were calculated for nor-
mally distributed data, and Spearman’s correlation coefficients 
(rs) for not normally distributed data. 
Seven multiple linear regression models were made to assess the 
predictive value of the independent variables (sex, age, visibility 
of the keloid, number of keloids as well as all the PSAS variables: 
pain, itch, colour, stiffness, thickness, and irregularity) on HRQL 
outcomes. Non-normal dependent variables were root-transformed 
in order to obtain a normal distribution. Data were entered, fol-
lowed by a backward procedure, in which non-significant effects 
(p > 0.10) were removed from the models. Regression coefficients 
were standardized (betas) to allow for better comparison of dif-
ferent factors in the model, independent of the units of measure-
ment of the variables. A beta of 0.1 indicates a small effect, 0.3 
a medium effect, and 0.5 a large effect. R2 represents the amount 
of variability in the outcome that is accounted for by indicators 
used in the model. 
All analyses were executed using IBM® SPSS Statistics version 
22 for Mac OSX. Two-sided p-values ≤ 0.05 were regarded as 
statistically significant.
Ethical considerations
The Ethics Board Committees of both participating academic 
hospitals concluded that this study was exempt from approval 
because of absence of any risk to participants.
RESULTS
Patient characteristics
Of the 280 eligible patients who were invited by post to 
participate in the study, 70 could not be reached after 3 
attempts, 17 no longer had a keloid, 38 indicated they 
did not wish to participate, 8 had another skin disease 
besides keloids, and 41 did not complete the online sur-
vey, leaving 106 patients who successfully completed 
the questionnaires (36 from a dermatology department, 
and 70 from a plastic surgery department). The response 
rate was 57%. Socio-demographic and clinical charac-
teristics of the responders are shown in Table I. Of the 
non-responders, 49% were male and the mean age was 
39.1 years (SD 13.0, range 18–72 years), which was 
comparable to the responders (Table I).
Generic health-related quality of life of keloid patients 
The outcomes for all the individual dimensions of the SF-
36, as well as the PCSs and MCSs of the keloid patients 
were compared with an age-matched Dutch reference 
population, including healthy and unhealthy subjects 
with a living area and sex distribution comparable to 
our study population (Table II) (16). Compared with the 
reference population, keloid patients scored considerably 
lower on the SF-36 dimensions bodily pain, vitality, and 
social functioning as well as on the MCS, meaning that 
keloid patients reported a worse mental HRQL. The ef-
fect size for the MCS was –0.28, indicating a small effect 
(20). This is in contrast to the PCS, which was similar to 
that of the reference population (Table II). 
Associated factors and predictors of health-related 
quality of life of keloid patients 
The relationship between HRQL and the individual 
independent variables sex, age, skin colour, visibility 
of keloids, quantity of keloids, disease duration, hos-
pital department, and all PSAS items were analysed. 
Pain and itch were correlated to all Skindex-29 scales 
(ranging from rs 0.44 to 0.75, p < 0.001), to both SF-36 
component summary scores (ranging from rs –0.24 
to –0.29, p < 0.012) and the EQ-5D-5L index (–0.54, 
p < 0.001), meaning pain and itch were associated with 
nearly all HRQL measures. In addition, scar stiffness, 
thickness, and irregularity showed high correlations 
with HRQL outcomes. Duration of disease, skin colour, 
and department type (dermatology vs plastic surgery) 
showed no significant association with HRQL. Female 
sex correlated with worse outcomes on emotional, 
symptomatic, and sum scores of the Skindex-29 (rp 
0.23–0.24, p < 0.017).
Regression analyses revealed that pain was a negative 
HRQL indicator in 6 (moderate effect on all Skindex-29 
scales, small effect on PCS, and moderate effect on EQ-
5D-5L index), and itch in 4 (large effect on symptomatic 
Skindex-29 and moderate effect on Skindex-29 sum, 
MCS and EQ-5D-5L) models, respectively, making 
these the most consistent and strongest indicators of 
HRQL. Besides pain and itch, other indicators were age 
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on MCS), number of keloids (small effect on emotional, 
functional and sum Skindex-29), scar stiffness (mode-
rate effect on PCS and EQ-5D-5L index) and irregu-
larity (small effect on emotional, functional and sum 
Skindex-29). Keloid colour was present as indicator in 
2 models, but a more aberrant scar colour improved the 
HRQL, while there was no proof of multi-collinearity. 
The Skindex-29 models could explain between 29% 
and 60% of the variability in outcome (R2) and for the 
PCS, MCS, and EQ-5D-5L index it was 17%, 11%, and 
34%, respectively (Table III).
DISCUSSION
In this study HRQL, specifically emotional wellbeing, 
of patients with keloid disease was considerably lower 
compared with a matched reference population on the 
generic instrument SF-36. This corresponds with the 
large proportion of keloid patients with severe impair-
ment on the emotional scale of the Skindex-29, while 
the symptomatic and functional Skindex-29 scales were 
less affected, with 27% and 25% (12). Reinholz et al. (9) 
found similar results on HRQL of keloid patients using 
the Dermatology Life Quality Index (DLQI); specifically 
symptoms and feelings were affected.
Factors associated with worse HRQL of keloid 
patients were pain and itch symptoms that are more 
prominent in keloids than in other scar types (12). 
Remarkably, cosmetic issues correlated less, or even 
inconsistently with HRQL. These findings support 
priority setting, as surgery for cosmetic issues can be 
interpreted as “luxury healthcare”, instead of a medi-
cal need, which relates to its current lower priority in 
health policy decision-making (21). The current study 
showed that HRQL can be considerably impaired in 
patients with keloid disease, causing reasonable doubt 
on current priority setting. 
Skin colour, age, and disease duration did not interact 
with HRQL. Generally, pain and itch are frequently re-
ported symptoms of keloid disease (1). Of the patients 
with pain and itch scores >3, 70% had severe emotional 
HRQL impairment (Skindex-29) compared with 16% in 
the group of patients that had low pain and itch scores. 
Moreover, we showed that pain and itch were consis-
tently and strongly associated with HRQL impairment.
A previous study on HRQL in patients with scars found 
less pain (26%) and itch (44%) complaints and minimal 
Table I. Characteristics of the keloid patients (n = 106) analysed 
in this study
Characteristics
Age, years, mean (SD) [range] 38.6 (11.9) [18–63]




Skin colour (Fitzpatrick), n (%)
1–2 Light 23 (21.7)
3–4 Coloured 44 (41.5)
5–6 Dark 38 (35.8)




Secondary symptoms, n (%)
Pain & itch ≤ 3 27 (25.5)
Pain > 3 3 (2.8)
Itch > 3 22 (20.8)
Pain & itch > 3 54 (50.9)










Keloids visible (wearing normal clothing), n (%)
No 40 (37.7)
Yes 66 (62.3)
Origin of keloid, n (%)




Traumatic injury 6 (5.7)
Unknown 25 (23.6)
Previous keloid treatmenta, n (%)
None 4 (3.8)
Silicone sheets 56 (52.8)
Pressure therapy 4 (3.8)
Intralesional corticosteroid 82 (77.4)
Excision 25 (23.6)
Excision with additive 27 (25.5)
Radiation therapy 12 (11.3)
Cryotherapy 27 (25.5)
Laser 32 (30.2)
PSAS, mean (SD) [range]
Pain 4.21 (2.82) [1–10]
Itch 5.84 (2.97) [1–10]
Colour 6.68 (2.52) [1–10]
Stiffness 7.00 (2.43) [1–10]
Thickness 7.73 (2.05) [1–10]
Irregularity 7.54 (2.21) [1–10]
Overall opinion 8.13 (2.05) [2–10]
aMultiple answers were possible, summed percentages exceed 100%.
SD: standard deviation; PSAS: patient part of the Patient and Observer Scar 
Assessment Scale.
Table II. Overview of SF-36 scores of the keloid patients compared 
with an age-matched reference population
Keloid disease 
population 











Physical function 90.4 (16.3) 88.6 (19.0) 0.12 0.17
Role physical 86.8 (29.1) 81.5 (33.4) 0.16 0.07
Bodily pain 72.8 (25.2) 81.7 (23.3) –0.38 < 0.01
General health 73.4 (19.0) 72.6 (19.9) 0.04 0.67
Vitality 63.3 (21.2) 68.7 (18.9) –0.28 0.01
Social function 80.1 (24.1) 85.9 (20.2) –0.29 0.02
Role emotion 81.4 (36.0) 83.2 (32.5) –0.05 0.63
Mental health 72.0 (20.7) 75.7 (17.5) –0.21 0.07
PCS 50.4 (8.7) 50.0 (10.0) 0.05 0.60
MCS 47.2 (12.0) 50.0 (10.0) –0.28 0.02
SF-36: the 36-item Short Form Health Survey; SD: standard deviation; PCS: 
physical component summary score; MCS: mental component summary score; 
pooled-SD: age-matched, urban (Amsterdam) reference population adapted from 
Aaronson et al. (16) with comparable proportions males (46%). PCSs and MCSs 
are norm transformed to the reference population with a mean 50 and SD 10. 
The study population is compared with the reference population; the effect size is 
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correlations of pain and itch with emotional HRQL (4). 
These discrepancies can be explained by the large dif-
ferences between keloids and other scar types, which are 
less severe than keloids. 
Furtado et al. (8) specifically studied keloid patients 
and similarly found that pain and itch correlated with 
worse HRQL. They showed non-visible keloids resulted 
in worse physical HRQL, while we could not find an 
effect of keloid visibility on physical HRQL. However, 
we did find impairment of mental HRQL in patients 
with a visible keloid. Visible keloids could affect HRQL 
because they are socially more disturbing. Furtado et al. 
(8) explained that in their population non-visible keloids 
were long-existing recalcitrant pre-sternal keloids, resul-
ting in worse HRQL in this group. 
High-profile reviews on pathological scarring focused 
mainly on the morphological and disfiguring aspects of 
keloid disease, and considered the accompanying symp-
toms of secondary concern (22–24). However, the results 
of our study challenge this view by clearly showing 
that itch and pain symptoms are the main indicators of 
HRQL impairment. Consequently, we believe that these 
symptoms should be of primary concern in the evaluation 
and treatment of keloid disease, as well as in scientific 
research on this topic. 
Limitation
A limitation of the current study is that all patients were 
recruited from academic hospitals, possibly resulting in 
a selection bias towards patients with a relatively high 
burden of disease. This could limit the generalizability 
of the current results to the entire keloid patient popula-
tion. On the other hand, the patients from the present 
study represent those who seek treatment from a medical 
specialist. The sample was evenly distributed on sex and 
contained a variety of skin types, disease durations, age 
groups, and other clinical characteristics and had similar 
composition to other population-samples described in 
the literature (9, 12). The incomplete response rate could 
also have introduced selection bias.
Another issue could be the cross-sectional design with 
online questionnaires for scar quality and HRQL assess-
ment that completely relied on self-reports. Patients may 
think that exaggerating their burden may result in better 
treatment, a higher chance of insurance fees or sick leave. 
These disease induced benefits, or secondary gains, may 
have influenced their answers. However, a large part of 
our study group was not currently under treatment or 
clinically re-evaluated, and was probably less affected 
by secondary gains. 
Conclusion
Our previous report (12) and the present report show 
that keloid disease is strongly associated with mental 
and emotional HRQL impairment, which suggests a high 
need for effective treatment and thus a priority in healt-
hcare policymaking. HRQL is most severely affected 
in patients with an itching or painful keloid, suggesting 
that, in these patients, cosmetic appearance is less of a 
concern than physical symptoms.
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